Pandemic Novel 2009 H1N1 Influenza: What Have We Learned?

ABSTRACT

In March 2009, cases of influenza-like illness in Mexico caused by a novel H1N1 virus containing genes from swine, avian, and human influenza strains were reported. Within several weeks, 2009 H1N1 disseminated rapidly and was the predominant influenza strain globally. On June 11, 2009, the World Health Organization declared that criteria for an influenza pandemic had been met. Concern that this pandemic would rival the 1918 pandemic was high. Fortunately, that was not the case. Influenza-related disease activity peaked in late October to November 2009. By August 2010, the H1N1 influenza virus had moved into the postpandemic period. During the 2010–2011 season, influenza A H3N2 has been the predominant serotype, but the 2009 H1N1 continues to co-circulate with H3N2 and B strains. In contrast to previous seasonal influenza strains, the novel 2009 H1N1 strain preferentially affected young adults, with a clustering of severe and fatal cases in adults between the ages of 30 and 50 years. Additionally, H1N1 displayed a heightened potential for severe lung injury as well as gastrointestinal symptoms. Risk factors for severe disease included obesity, morbid obesity, pregnancy, immunosuppression, asthma (in children), chronic obstructive pulmonary disease, neurological disorders, other comorbidities, HIV-infection, poverty, and lack of access to care. However, >25% of deaths were in previously healthy individuals. Molecular tools for identifying 2009 H1N1 were rapidly developed, but the volume of samples quickly overwhelmed available laboratory services. Further, in the early phases of the pandemic, the volume of patients presenting to emergency rooms, acute care clinics, and physician's offices overwhelmed health care resources. Fortunately, most cases were mild; in the United States, only one in 400 required intensive care unit care, and one in 2000 died. Because most infected individuals have mild, self-limited disease, the risk/benefit assessment for early access to antiviral agents must balance the potential benefit for reducing transmission, disease severity, and burden on health care providers against the potential for dissemination of viral resistance and drug-related adverse events. Monovalent vaccines against 2009 H1N1 were developed and ready for distribution by September 2009, but initial supplies were inadequate to impact the bulk of cases that occurred in the Northern Hemisphere between April and September 2009. Continued efforts to develop universal vaccines and improve access to effective vaccines are critical.

KEYWORDS

Novel 2009 H1N1 - influenza - swine influenza - pandemic

REFERENCES

• 1 World now at the start of 2009 influenza pandemic [news release]. 2009. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html Accessed May 19, 2011
• 2 Influenza updates. September 10, 2010. http://www.who.int/csr/don/2010_09_10/en/index.html Accessed April 18, 2011
• 3 Centers for Disease Control and Prevention (CDC) . Update: influenza activity—United States, October 3, 2010–February 5, 2011.  MMWR Morb Mortal Wkly Rep. 2011;  60 (6) 175-181
• 4 Girard M P, Tam J S, Assossou O M, Kieny M P. The 2009 A (H1N1) influenza virus pandemic: a review.  Vaccine. 2010;  28 (31) 4895-4902
• 5 Garten R J, Davis C T, Russell C A et al.. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.  Science. 2009;  325 (5937) 197-201
• 6 Vallat B. Flu: no sign so far that the human pandemic is spread by pigs.  Nature. 2009;  460 (7256) 683
• 7 Childs R A, Palma A S, Wharton S et al.. Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray.  Nat Biotechnol. 2009;  27 (9) 797-799
• 8 Shieh W-J, Blau D M, Denison A M et al.. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States.  Am J Pathol. 2010;  177 (1) 166-175
• 9 Gill J R, Sheng Z M, Ely S F et al.. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections.  Arch Pathol Lab Med. 2010;  134 (2) 235-243
• 10 Mauad T, Hajjar L A, Callegari G D et al.. Lung pathology in fatal novel human influenza A (H1N1) infection.  Am J Respir Crit Care Med. 2010;  181 (1) 72-79
• 11 Kawaoka Y, Webster R G. Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells.  Proc Natl Acad Sci U S A. 1988;  85 (2) 324-328
• 12 Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses.  Science. 2001;  293 (5536) 1840-1842
• 13 De Serres G, Rouleau I, Hamelin M-E et al.. Contagious period for pandemic (H1N1) 2009.  Emerg Infect Dis. 2010;  16 (5) 783-788
• 14 Cao B, Li X W, Mao Y National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.  N Engl J Med. 2009;  361 (26) 2507-2517
• 15 Fleury H, Burrel S, Balick Weber C et al.. Prolonged shedding of influenza A(H1N1)v virus: two case reports from France 2009.  Euro Surveill. 2009;  14 (49) 14
• 16 Lee N. Pathogenesis of pandemic H1N1 in humans. Paper presented at the XII International Symposium on Respiratory Viral Infections; March 11–14, 2010; Taipei, Taiwan
• 17 Bautista E, Chotpitayasunondh T, Gao Z Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection.  N Engl J Med. 2010;  362 (18) 1708-1719
• 18 Chen M I, Lee V J, Lim W Y et al.. 2009 influenza A(H1N1) seroconversion rates and risk factors among distinct adult cohorts in Singapore.  JAMA. 2010;  303 (14) 1383-1391
• 19 Cauchemez S, Donnelly C A, Reed C et al.. Household transmission of 2009 pandemic influenza A (H1N1) virus in the United States.  N Engl J Med. 2009;  361 (27) 2619-2627
• 20 Lessler J, Reich N G, Cummings D A, Nair H P, Jordan H T, Thompson N. New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team . Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school.  N Engl J Med. 2009;  361 (27) 2628-2636
• 21 Shrestha S S, Swerdlow D L, Borse R H et al.. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010).  Clin Infect Dis. 2011;  52 (Suppl 1) S75-S82
• 22 Louie J K, Acosta M, Winter K California Pandemic (H1N1) Working Group et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.  JAMA. 2009;  302 (17) 1896-1902
• 23 Jain S, Kamimoto L, Bramley A M 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.  N Engl J Med. 2009;  361 (20) 1935-1944
• 24 Archer B, Cohen C, Naidoo D et al.. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases.  Euro Surveill. 2009;  14 (42) 14
• 25 Yu H, Feng Z, Uyeki T M et al.. Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China.  Clin Infect Dis. 2011;  52 (4) 457-465
• 26 Louie J K, Acosta M, Samuel M C California Pandemic (H1N1) Working Group et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1).  Clin Infect Dis. 2011;  52 (3) 301-312
• 27 Piwpankaew Y, Monteerarat Y, Suptawiwat O, Puthavathana P, Uipresertkul M, Auewarakul P. Distribution of viral RNA, sialic acid receptor, and pathology in H5N1 avian influenza patients.  APMIS. 2010;  118 (11) 895-902
• 28 Dawood F S, Jain S, Finelli L Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans.  N Engl J Med. 2009;  360 (25) 2605-2615
• 29 Kumar A, Zarychanski R, Pinto R Canadian Critical Care Trials Group H1N1 Collaborative et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada.  JAMA. 2009;  302 (17) 1872-1879
• 30 Webb S A, Pettilä V, Seppelt I ANZIC Influenza Investigators et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand.  N Engl J Med. 2009;  361 (20) 1925-1934
• 31 Leung G M, Nicoll A. Reflections on pandemic (H1N1) 2009 and the international response.  PLoS Med. 2010;  7 (10) 7
• 32 The role of the Health Protection Agency in the “containment” phase during the first wave of pandemic influenza in England in 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1274088320581 Accessed May 2, 2011
• 33 Wu J T, Cowling B J, Lau E H et al.. School closure and mitigation of pandemic (H1N1) 2009, Hong Kong.  Emerg Infect Dis. 2010;  16 (3) 538-541
• 34 Kawaguchi R, Miyazono M, Noda T, Takayama Y, Sasai Y, Iso H. Influenza (H1N1) 2009 outbreak and school closure, Osaka Prefecture, Japan.  Emerg Infect Dis. 2009;  15 (10) 1685
• 35 Jarquin V G, Callahan D B, Cohen N J et al.. Effect of school closure from pandemic (H1N1) 2009, Chicago, Illinois, USA.  Emerg Infect Dis. 2011;  17 (4) 751-753
• 36 Technical Report for State and Local Public Health Officials and School Administrators on CDC Guidance for School (K-12) Responses to Influenza during the 2009–2010 School Year. 2009. http://www.cdc.gov/h1n1flu/schools/technicalreport.htm Accessed May 2, 2011
• 37 FDA approves vaccines for 2009 H1N1 influenza virus: approval provides important tool to fight pandemic [news release]. 2009. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm182399.htm Accessed May 3, 2011
• 38 Liao Q, Cowling B J, Lam W W, Fielding R. Factors affecting intention to receive and self-reported receipt of 2009 pandemic (H1N1) vaccine in Hong Kong: a longitudinal study.  PLoS ONE. 2011;  6 (3) e17713
• 39 Greenberg M E, Lai M H, Hartel G F et al.. Response to a monovalent 2009 influenza A (H1N1) vaccine.  N Engl J Med. 2009;  361 (25) 2405-2413
• 40 Zimmer S M, Burke D S. Historical perspective—emergence of influenza A (H1N1) viruses.  N Engl J Med. 2009;  361 (3) 279-285
• 41 Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché M K, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.  Lancet. 2010;  375 (9708) 41-48
• 42 Flynn P M, Nachman S, Spector S A et al.. Safety and immunogenicity of 2009 H1N1 influenza immunization in HIV-1 perinatally infected children and youth. Paper presented at: Infectious Disease Society of America 48th Annual Meeting; October 23, 2010; Vancouver, British Columbia, Canada
• 43 Weinberg A, Muresan P, Fenton T et al.. Safety and Immunogenicity of two doses of monovalent pandemic H1N1 (pH1N1) influenza vaccine in HIV-infected pregnant women. Paper presented at: Infectious Disease Society of America 48th Annual Meeting; October 23, 2010; Vancouver, British Columbia, Canada
• 44 Vellozzi C, Broder K R, Haber P et al.. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010.  Vaccine. 2010;  28 (45) 7248-7255
• 45 Centers for Disease Control and Prevention (CDC) . Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine—United States, 2009–2010.  MMWR Morb Mortal Wkly Rep. 2010;  59 (21) 657-661
• 46 Statement on narcolepsy and vaccination. 2011. http://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/ Accessed May 19, 2011
• 47 Nistal-Villán E, García-Sastre A. New prospects for the rational design of antivirals.  Nat Med. 2009;  15 (11) 1253-1254
• 48 Chowell G, Bertozzi S M, Colchero M A et al.. Severe respiratory disease concurrent with the circulation of H1N1 influenza.  N Engl J Med. 2009;  361 (7) 674-679
• 49 Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009.  Wkly Epidemiol Rec. 2009;  84 (30) 301-304
• 50 Presanis A M, De Angelis D, Hagy A New York City Swine Flu Investigation Team et al. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis.  PLoS Med. 2009;  6 (12) e1000207
• 51 Nicoll A, Ammon A, Amato Gauci A et al.. Experience and lessons from surveillance and studies of the 2009 pandemic in Europe.  Public Health. 2010;  124 (1) 14-23
• 52 Lee B Y, Brown S T, Cooley P et al.. Vaccination deep into a pandemic wave potential mechanisms for a “third wave” and the impact of vaccination.  Am J Prev Med. 2010;  39 (5) e21-e29
• 53 Furuya Y, Chan J, Regner M et al.. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by gamma-irradiated influenza A viruses.  J Virol. 2010;  84 (9) 4212-4221
• 54 Rudolph W, Ben Yedidia T. A universal influenza vaccine: where are we in the pursuit of this “Holy Grail”?.  Hum Vaccin. 2011;  7 (1) 10-11